146 results on '"Park, Wungki"'
Search Results
102. The Concept of Biosimilars: From Characterization to Evolution—A Narrative Review
- Author
-
Farhat, Fadi, primary, Torres, Alfredo, additional, Park, Wungki, additional, de Lima Lopes, Gilberto, additional, Mudad, Raja, additional, Ikpeazu, Chukwuemeka, additional, and Abi Aad, Simon, additional
- Published
- 2017
- Full Text
- View/download PDF
103. Long-term survival based on pathologic response to neoadjuvant therapy in esophageal cancer
- Author
-
Tiesi, Gregory, primary, Park, Wungki, additional, Gunder, Meredith, additional, Rubio, Gustavo, additional, Berger, Michael, additional, Ardalan, Bach, additional, Livingstone, Alan, additional, and Franceschi, Dido, additional
- Published
- 2017
- Full Text
- View/download PDF
104. P3.02c-081 Complete Blood Count Parameters as Predictive Factors in Patients with Advanced Non-Small Cell Lung Cancer Treated with Nivolumab
- Author
-
Saravia, Diana, primary, Laderian, Bahar, additional, Park, Wungki, additional, Desai, Amrita, additional, Vargas, Fernando, additional, Elias, Roy, additional, Warsch, Sean, additional, Mudad, Raja, additional, Ikpeazu, Chukwuemeka, additional, Ishkanian, Adrian, additional, Balfe, Lisa, additional, and Jahanzeb, Mohammad, additional
- Published
- 2017
- Full Text
- View/download PDF
105. P3.02b-092 Central Nervous System (CNS) Responses to Osimertinib in Brain Metastases from Lung Cancer (NSCLC) with T790M: Effectiveness of the 80 Mg Dose
- Author
-
Park, Wungki, primary and Mudad, Raja, additional
- Published
- 2017
- Full Text
- View/download PDF
106. Reply to N. Fazio.
- Author
-
O'Reilly, Eileen M., Park, Wungki, and Kelsen, David P.
- Published
- 2020
- Full Text
- View/download PDF
107. Cost-effectiveness of Osimertinib in the First-Line Treatment of Patients With EGFR-Mutated Advanced Non–Small Cell Lung Cancer.
- Author
-
Aguiar, Pedro N., Haaland, Benjamin, Park, Wungki, San Tan, Pui, del Giglio, Auro, and de Lima Lopes, Gilberto
- Published
- 2018
- Full Text
- View/download PDF
108. The Concept of Biosimilars: From Characterization to Evolution—A Narrative Review.
- Author
-
Farhat, Fadi, Torres, Alfredo, Park, Wungki, de Lima Lopes, Gilberto, Mudad, Raja, Ikpeazu, Chukwuemeka, and Abi Aad, Simon
- Subjects
GOVERNMENT agencies ,MARKETING ,MEDLINE ,ONLINE information services ,ORGANIZATIONAL effectiveness ,PHARMACEUTICAL industry ,SYSTEMATIC reviews ,PHARMACY ,HUMAN growth hormone ,ECONOMICS - Abstract
Abstract: Biologic agents are currently the fastest emerging segment of drug expenditure. Unlike chemically synthesized small‐molecule drugs, biologics are more complex, medicinal products produced by a living organism. They have become part of the standard of care in the treatment of a large variety of diseases, such as growth disorders, autoimmune diseases, cancer, cardiovascular illnesses, hemophilia, and rare genetic conditions, to name a few. Biosimilars, which are copies of biologics that are highly similar, were introduced in the market with an aim to offer efficacy that is not clinically different from the originator or reference product, at lower prices. We aim to clarify the concept of biosimilar, from definitions, history, market entry, challenges faced, and future evolution. For that purpose, we performed a literature search on the sites of the medicines regulatory agencies and PubMed from 1990 to 2014 with the keywords “biosimilars,” “market,” and “regulatory.” In 2006, the first biosimilar, somatropin [rDNA origin], was marketed and led the way for biosimilar drug manufacturing. As a result, manufacturers have entered a diversified competition, facing challenges in manufacturing these complex agents, such as immunogenicity and efficiency. Biosimilars are set to evolve differently in various markets, namely the U.S., Japan, the European Union, and the “pharmerging” economies. Implications for Practice: This article highlights the importance of biosimilars, as a cost‐cutting strategy, in the delivery of state‐of‐the‐art health care in developing countries, at a fraction of what a reference biological agent would cost. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
109. A phase I/II study of durvalumab and stereotactic ablative body radiotherapy (SABR) in locally advanced (LA) and borderline resectable (BR) pancreatic cancer.
- Author
-
Tuli, Richard, Keane, Fergus, Schoenfeld, Joshua David, O'Connor, Catherine, White, Charlie, Chou, Joanne F., Schwartz, Carly, Larsen, Mary, Brenner, Robin, Park, Wungki, Nissen, Nicholas, Zervoudakis, Alice, Varghese, Anna M., Yu, Kenneth H., Capanu, Marinela, Vardhana, Santosha, Hendifar, Andrew Eugene, Reyngold, Marsha, Crane, Christopher H., and O'Reilly, Eileen Mary
- Published
- 2023
- Full Text
- View/download PDF
110. Clinical utility of next generation sequencing (NGS) on circulating tumor DNA (ctDNA) in patients (pts) with pancreatic cancer (PC).
- Author
-
Keane, Fergus, Saadat, Lily, O'Connor, Catherine, Chou, Joanne F., Brannon, Angela Rose, Cowzer, Darren, Crowley, Fionnuala, Debnath, Neha, Bowman, Anita, Xu, Fei, Park, Wungki, Zervoudakis, Alice, Balogun, Fiyinfolu, Varghese, Anna M., Yu, Kenneth H., Kelsen, David Paul, Capanu, Marinela, Berger, Michael F., Wei, Alice Chia-chi, and O'Reilly, Eileen Mary
- Published
- 2023
- Full Text
- View/download PDF
111. Phase 2 trial of pembrolizumab and olaparib (POLAR) maintenance for patients (pts) with metastatic pancreatic cancer (mPDAC): Two cohorts B non-core homologous recombination deficiency (HRD) and C exceptional response to platinum-therapy.
- Author
-
Park, Wungki, O'Connor, Catherine, Chou, Joanne F., Schwartz, Carly, Varghese, Anna M., Larsen, Mary, Balogun, Fiyinfolu, Brenner, Robin, Yu, Kenneth H., Diguglielmo, Erin, Umeda, Shigeaki, Karnoub, Elias, Keane, Fergus, Zhang, Haochen, Joshi, Smita Suhas, Riaz, Nadeem, Kelsen, David Paul, Capanu, Marinela, Iacobuzio-Donahue, Christine A, and O'Reilly, Eileen Mary
- Published
- 2023
- Full Text
- View/download PDF
112. Evaluation of microsatellite instability status, a definitive predictive biomarker for immune checkpoint inhibitors (ICI), in underrepresented minorities (URM) with gastrointestinal (GI) cancers.
- Author
-
Balogun, Fiyinfolu, Altoe, Mirella, O'Connor, Catherine, Chowdhury, Nobel, Cercek, Andrea, Lee, Choong-kun, Foote, Michael Bonner, Kim, Daehee, Maron, Steven Brad, Kim, Dae Won, Ronski, Karyn, Park, Joon Oh, Chao, Calvin Y., Janjigian, Yelena Y., Abou-Alfa, Ghassan K., Diaz, Luis A., O'Reilly, Eileen Mary, Sanchez-Vega, Francisco, Chakravarty, Debyani, and Park, Wungki
- Published
- 2023
- Full Text
- View/download PDF
113. Heat shock protein 90 promotes epithelial to mesenchymal transition, invasion, and migration in colorectal cancer
- Author
-
Nagaraju, Ganji Purnachandra, primary, Long, Tua‐Elisabeth, additional, Park, Wungki, additional, Landry, Jerome C., additional, Taliaferro‐Smith, LaTonia, additional, Farris, Alton B., additional, Diaz, Roberto, additional, and El‐Rayes, Bassel F., additional
- Published
- 2014
- Full Text
- View/download PDF
114. Outcomes of biliary stents in advanced pancreatic cancer in the era of improved systemic therapy.
- Author
-
Park, Wungki, primary, Mankal, Pavan Kumar, additional, and O'Reilly, Eileen Mary, additional
- Published
- 2014
- Full Text
- View/download PDF
115. Crosstalk from survival to necrotic death coexists in DU-145 cells by curcumin treatment
- Author
-
Kang, Dongxu, primary, Park, Wungki, additional, Lee, Seungha, additional, Kim, Joo-Hang, additional, and Song, Jae J., additional
- Published
- 2013
- Full Text
- View/download PDF
116. New Perspectives of Curcumin in Cancer Prevention
- Author
-
Park, Wungki, primary, Amin, A.R.M. Ruhul, additional, Chen, Zhuo Georgia, additional, and Shin, Dong M., additional
- Published
- 2013
- Full Text
- View/download PDF
117. Abstract 2707: Heat shock protein 90 functional inhibition regulates epithelial to mesenchymal transformation, invasion and migration via NF-kB and HIF-1α signaling in colorectal cancer.
- Author
-
Ganji, Purnachandra, primary, Long, Tua-Elisabeth, additional, Mummareddi, Phani Madhuri, additional, Park, Wungki, additional, Willingham, Field F., additional, Landry, Jerome C., additional, Sullivan, Patrick, additional, Taliaferro-Smith, LaTonia, additional, Diaz, Roberto, additional, and El-Rayes, Bassel, additional
- Published
- 2013
- Full Text
- View/download PDF
118. A comparative analysis of locoregional therapy (hyperthermic intraperitoneal chemotherapy [HIPEC]) and systemic chemotherapy (CT) following cytoreductive surgery in patients (pts) with disseminated mucinous appendiceal cancers (MACA).
- Author
-
Bekaii-Saab, Tanios S., primary, Martin, Ludmila Katherine, additional, Vallabhaneni, Geetha D., additional, Park, Wungki, additional, Staley, Charles A., additional, Maithel, Shishir Kumar, additional, Wang, Zhibo, additional, Chen, Zhengjia, additional, and El-Rayes, Bassel F., additional
- Published
- 2012
- Full Text
- View/download PDF
119. Clinicopathologic feature and outcome of appendiceal goblet cell carcinoid and neuroendocrine tumor.
- Author
-
Park, Wungki, primary, Vallabhaneni, Geetha D., additional, Martin, Ludmila Katherine, additional, Adsay, Volkan, additional, Staley, Charles A., additional, Maithel, Shishir Kumar, additional, Wang, Zhibo, additional, Chen, Zhengjia, additional, El-Rayes, Bassel F, additional, and Bekaii-Saab, Tanios S., additional
- Published
- 2012
- Full Text
- View/download PDF
120. Abstract 3119: A synthetic lethal screen identifies genetic determinants for gemcitabine sensitivity in pancreatic cancer
- Author
-
Landry, Jerome C., primary, Pantazides, Brooke G., additional, Park, Wungki, additional, Shelton, Joseph W., additional, Maithel, Shishir K., additional, El-Rayes, Bassel, additional, and Yu, David S., additional
- Published
- 2012
- Full Text
- View/download PDF
121. Abstract 2273: Autophagic cell death induced by curcumin is mediated by p38/Beclin 1 to crosstalk with apoptotic cell death in DU145 cells
- Author
-
Kang, Dongxu, primary, Park, Wungki, additional, Kim, Joo-Hang, additional, and Song, Jae Jin, additional
- Published
- 2012
- Full Text
- View/download PDF
122. Abstract 2872: Functional inhibition of HSP90 potentiates the effects of ionizing radiation in colorectal cancer
- Author
-
Nagaraju, Ganji Purnachandra, primary, Wen, Jing, additional, El-Rayes, Bassel F., additional, Landry, Jerome C., additional, Park, Wungki, additional, and Diaz, Roberto, additional
- Published
- 2012
- Full Text
- View/download PDF
123. A dual‐targeting antibody against EGFR‐VEGF for lung and head and neck cancer treatment
- Author
-
Zhang, Hongzheng, primary, Yun, Sujin, additional, Batuwangala, Thil D., additional, Steward, Michael, additional, Holmes, Steve D., additional, Pan, Lin, additional, Tighiouart, Mourad, additional, Shin, Hyung Ju C., additional, Koenig, Lydia, additional, Park, Wungki, additional, Rycroft, Daniel, additional, Nannapaneni, Sreenivas, additional, Wang, Yuxiang, additional, Chen, Zhuo (Georgia), additional, and Shin, Dong M., additional
- Published
- 2011
- Full Text
- View/download PDF
124. Abstract C42: Survival signals differentially turn on during TRAIL or curcumin/TRAIL treatment
- Author
-
Oh, Seeun, primary, Kim, Joo-Hang, additional, Song, Jae J., additional, Kim, Jina, additional, Yoon, Hyo R., additional, Kang, Sujin, additional, Park, Wungki, additional, Hong, Kijae, additional, Kim, So Y., additional, and Choi, Hye J., additional
- Published
- 2011
- Full Text
- View/download PDF
125. Extended Mutational Profiling By MSK-IMPACTTMIdentifies Mutations Predicting Thromboembolic Risk in Patients with Solid Tumor Malignancy
- Author
-
Dunbar, Andrew, Bolton, Kelly, Devlin, Sean M., Sanchez-Vega, Francisco, Gao, Jianjiong, Mones, Jodi V., Wills, Jonathan M., Kelly, Daniel, Farina, Mirko, Kishore, Sirish, Juluru, Krishna, Iyengar, Neil, Hyman, David M., Zehir, Ahmet, Park, Wungki, Khorana, Alok A, Soff, Gerald A., and Mantha, Simon
- Published
- 2019
- Full Text
- View/download PDF
126. Biomarker analysis from a phase II multi-institutional study of nivolumab in patients with advanced refractory biliary tract cancer.
- Author
-
Kim, Dae Won, Kim, Young-chul, Kovari, Bence P., Chung, Vincent, Alese, Olatunji B., El-Rayes, Bassel F., Li, Daneng, Park, Wungki, and Kim, Richard D.
- Subjects
- *
RESEARCH , *NIVOLUMAB , *TUMOR markers , *DRUG resistance in cancer cells ,BILE duct tumors - Published
- 2022
- Full Text
- View/download PDF
127. Methylation Analyses Reveal Promoter Hypermethylation as a Rare Cause of "Second Hit" in Germline BRCA1-Associated Pancreatic Ductal Adenocarcinoma.
- Author
-
Zheng-Lin, Binbin, Rainone, Michael, Varghese, Anna M., Yu, Kenneth H., Park, Wungki, Berger, Michael, Mehine, Miika, Chou, Joanne, Capanu, Marinela, Mandelker, Diana, Stadler, Zsofia K., Birsoy, Ozge, Jairam, Sowmya, Yang, Ciyu, Li, Yirong, Wong, Donna, Benhamida, Jamal K, Ladanyi, Marc, Zhang, Liying, and O'Reilly, Eileen M.
- Subjects
- *
PANCREATIC duct , *METHYLATION , *GERM cells , *BRCA genes , *ADENOCARCINOMA , *METHYLGUANINE - Abstract
Background and Objective: Pancreatic ductal adenocarcinoma (PDAC) is characterized by the occurrence of pathogenic variants in BRCA1/2 in 5–6% of patients. Biallelic loss of BRCA1/2 enriches for response to platinum agents and poly (ADP-ribose) polymerase 1 inhibitors. There is a dearth of evidence on the mechanism of inactivation of the wild-type BRCA1 allele in PDAC tumors with a germline BRCA1 (gBRCA1) pathogenic or likely pathogenic variant (P/LPV). Herein, we examine promotor hypermethylation as a "second hit" mechanism in patients with gBRCA1-PDAC. Methods: We evaluated patients with PDAC who underwent Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT) somatic and germline testing from an institutional database. DNA isolated from tumor tissue and matched normal peripheral blood were sequenced by MSK-IMPACT. In patients with gBRCA1-PDAC, we examined the somatic BRCA1 mutation status and promotor methylation status of the tumor BRCA1 allele via a methylation array analysis. In patients with sufficient remaining DNA, a second methylation analysis by pyrosequencing was performed. Results: Of 1012 patients with PDAC, 19 (1.9%) were identified to harbor a gBRCA1 P/LPV. Fifteen patients underwent a methylation array and the mean percentage of BRCA1 promotor methylation was 3.62%. In seven patients in whom sufficient DNA was available, subsequent pyrosequencing confirmed an unmethylated BRCA1 promotor. Loss of heterozygosity was detected in 12 of 19 (63%, 95% confidence interval 38–84) patients, demonstrating loss of heterozygosity is the major molecular mechanism of BRCA1 inactivation in PDAC. Two (10.5%) cases had a somatic BRCA1 mutation. Conclusions: In patients with gBRCA1-P/LPV-PDAC, loss of heterozygosity is the main inactivating mechanism of the wild-type BRCA1 allele in the tumor, and methylation of the BRCA1 promoter is a distinctly uncommon occurrence. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
128. Distinct clinical outcomes and biological features of specific KRAS mutants in human pancreatic cancer.
- Author
-
McIntyre, Caitlin A., Grimont, Adrien, Park, Jiwoon, Meng, Yinuo, Sisso, Whitney J., Seier, Kenneth, Jang, Gun Ho, Walch, Henry, Aveson, Victoria G., Falvo, David J., Fall, William B., Chan, Christopher W., Wenger, Andrew, Ecker, Brett L., Pulvirenti, Alessandra, Gelfer, Rebecca, Zafra, Maria Paz, Schultz, Nikolaus, Park, Wungki, and O'Reilly, Eileen M.
- Subjects
- *
HUMAN biology , *PANCREATIC duct , *RAS oncogenes , *EPITHELIAL-mesenchymal transition , *PANCREATIC cancer - Abstract
KRAS mutations in pancreatic ductal adenocarcinoma (PDAC) are suggested to vary in oncogenicity but the implications for human patients have not been explored in depth. We examined 1,360 consecutive PDAC patients undergoing surgical resection and find that KRAS G12R mutations are enriched in early-stage (stage I) disease, owing not to smaller tumor size but increased node-negativity. KRAS G12R tumors are associated with decreased distant recurrence and improved survival as compared to KRAS G12D . To understand the biological underpinnings, we performed spatial profiling of 20 patients and bulk RNA-sequencing of 100 tumors, finding enhanced oncogenic signaling and epithelial-mesenchymal transition (EMT) in KRAS G12D and increased nuclear factor κB (NF-κB) signaling in KRAS G12R tumors. Orthogonal studies of mouse Kras G12R PDAC organoids show decreased migration and improved survival in orthotopic models. KRAS alterations in PDAC are thus associated with distinct presentation, clinical outcomes, and biological behavior, highlighting the prognostic value of mutational analysis and the importance of articulating mutation-specific PDAC biology. [Display omitted] • Early-stage (stage I) pancreatic cancer is enriched for KRAS G12R mutations • KRAS G12R patients have reduced nodal disease and distant recurrence and improved OS • Spatial profiling reveals decreased oncogenic signaling in human KRAS G12R tumors • Mouse Kras G12R PDAC organoids recapitulate transcriptional and survival differences McIntyre et al. demonstrate in an analysis of 1,360 patients the key features of early-stage pancreatic ductal adenocarcinoma (PDAC), including an enrichment of KRAS G12R disease that extensively associates with improved outcomes. Spatial profiling, transcriptomic analyses, and orthogonal mouse organoids recapitulate several allele-specific differences, underscoring the importance of mutation-specific biology in human PDAC. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
129. Outcomes associated with immune-related adverse events in metastatic non-small cell lung cancer treated with nivolumab: a pooled exploratory analysis from a global cohort.
- Author
-
Naqash, Abdul Rafeh, Ricciuti, Biagio, Owen, Dwight H., Florou, Vaia, Toi, Yukihiro, Cherry, Cynthia, Hafiz, Maida, De Giglio, Andrea, Muzaffar, Mavish, Patel, Sandip H., Sugawara, Shunichi, Burkart, Jarred, Park, Wungki, Chiari, Rita, Sugisaka, Jun, Otterson, Gregory A., de Lima Lopes, Gilberto, and Walker, Paul R.
- Subjects
- *
NON-small-cell lung carcinoma , *IMMUNE checkpoint inhibitors , *ADVERSE health care events , *GLOBAL analysis (Mathematics) , *TERMINATION of treatment - Abstract
Background: Immune-related adverse events (irAEs) comprise a distinct spectrum of auto-inflammatory manifestations triggered due to immune checkpoint inhibitors (ICI). Current data on the association of irAEs with outcomes in NSCLC treated with nivolumab are limited. Methods and objectives: We pooled data from 531 metastatic NSCLC patients from five centers treated with nivolumab after failing platinum-based chemotherapy. The primary objective was to investigate the relationship between irAEs with clinical benefit to nivolumab as well as to elucidate patterns of irAE-related ICI discontinuations and their impact on survival. Results: 33.0% (173/531) of patients treated with nivolumab were noted to have an irAE. Patients with irAEs had a significantly longer median PFS [6.1 vs. 3.1 months, HR 0.68 95% CI (0.55–0.85); p = 0.001] and OS [14.9 vs. 7.4 months, HR 0.66 95% CI (0.52–0.82); p < 0.001)] compared to those without irAEs. In multivariate analysis, the presence of irAEs showed a significantly better PFS [HR 0.69, 95% CI (0.55–0.87); p = 0.002] and a trend for better OS [HR 0.62, 95% CI (0.55–1.03); p = 0.057]. Patients with permanent ICI discontinuation secondary to index irAE had a significantly shorter median PFS [2.3 vs. 6.6 months, HR 1.74 95% CI (1.06–2.80); p = 0.02] and median OS [3.6 vs. 17.6 months; HR 2.61 95% CI (1.61–4.21); p < 0.001] compared to those that did not have permanent ICI discontinuation. Conclusions: Our pooled exploratory analysis demonstrates improved clinical benefit to nivolumab in NSCLC patients experiencing irAEs. We also observed negative impact of irAE-related treatment discontinuation on survival in this group of patients. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
130. Lynch Syndrome and Somatic Mismatch Repair Variants in Pancreas Cancer.
- Author
-
O'Connor CA, Harrold E, Lin D, Walch H, Gazzo A, Ranganathan M, Kane S, Keane F, Schoenfeld J, Moss D, Thurtle-Schmidt DM, Suehnholz SP, Chakravarty D, Balogun F, Varghese A, Yu K, Kelsen D, Latham A, Weigelt B, Park W, Stadler Z, and O'Reilly EM
- Abstract
Importance: Microsatellite (MS) instability (MSI-H) occurs frequently in Lynch syndrome (LS)-associated tumors and is associated with response to immune checkpoint blockade (ICB) therapy. MSI-H is conferred by germline or somatic variants in mismatch repair genes. The contribution of somatic oncogenesis to MSI-H in pancreatic cancer (PC) is unknown., Objective: To evaluate an LS-related PC cohort to define clinicogenomic features, describe somatic MSI-H cases (germline negative), characterize response to ICB, and guide preferred MS testing methods., Design, Setting, and Participants: This single-institution, retrospective analysis was conducted from March 2012 to July 2023 at Memorial Sloan Kettering Cancer Center and included 55 patients with PC and either an LS germline pathogenic variant (gPV) or somatic mismatch repair (MMR) variant., Main Outcomes and Measures: Composite MMR and MS status determined using orthogonal methods. An artificial intelligence classifier was used to account for low-cellularity specimens. Demographic and clinical data were abstracted from medical record. Zygosity status and somatic comutation landscape analyzed., Results: Fifty-five patients (23 women [42%]) had PC and an MMR variant: 32 (58%) had LS (LS cohort) and 23 (42%) had a somatic MMR variant (no germline pathogenic variant, somatic MMR cohort). In the LS cohort, 10 (31%) had gMSH2, 9 (28%) gMSH6, 8 (25%) gPMS2, 4 (13%) gMLH1, 1 (3%) gEPCAM. The median age at diagnosis was 68 years (range, 45-88 years). For composite MS status, 17 (59%) were MSI-H, 12 (41%) MS stable, and 3 MS unknown. Five cases were reclassified as MSI-H by the artificial intelligence classifier. In the somatic MMR cohort, 11 (48%) had MSH6, 7 (30%) MLH1, 3 (13%) MSH2, and 2 (9%) PMS2. The median age at diagnosis was 72 years (range, 66-85 years). For composite MS status, 10 (43%) were MSI-H, 11 (48%) MS stable, and 2 (9%) MS indeterminate. Six cases were reclassified as MSI-H by the artificial intelligence classifier. For the LS and somatic MMR cohorts, 20 received ICB (n = 17 MSI-H). The median ICB duration was 27.7 months (95% CI, 11.5 to not reached); the disease control rate was 80%., Conclusion: The results of this cross-sectional study suggest that MSI-H occurs due to LS or somatic oncogenesis in PC. Orthogonal MS testing is key in PC; the artificial intelligence classifier reclassified approximately 20% of cases, most of which were low cellularity. ICB for patients with LS or somatic MSI-H PC provided significant benefit.
- Published
- 2024
- Full Text
- View/download PDF
131. Precision medicine for pancreatic cancer: characterizing the clinicogenomic landscape and outcomes of KRAS G12C-mutated disease.
- Author
-
Keane F, Chou JF, Walch H, Schoenfeld J, Singhal A, Cowzer D, Harrold E, O'Connor CA, Park W, Varghese A, El Dika I, Balogun F, Yu KH, Capanu M, Schultz N, Yaeger R, and O'Reilly EM
- Subjects
- Humans, Female, Male, Aged, Middle Aged, DNA-Binding Proteins genetics, Smad4 Protein genetics, Nuclear Proteins genetics, Aged, 80 and over, Cyclin-Dependent Kinase Inhibitor p16 genetics, Tumor Suppressor Protein p53 genetics, Genomics, Adult, Biomarkers, Tumor genetics, Pancreatic Neoplasms genetics, Pancreatic Neoplasms drug therapy, Pancreatic Neoplasms mortality, Proto-Oncogene Proteins p21(ras) genetics, Precision Medicine, Mutation, Carcinoma, Pancreatic Ductal genetics, Carcinoma, Pancreatic Ductal drug therapy, Carcinoma, Pancreatic Ductal mortality, Transcription Factors genetics
- Abstract
Background: Mutated Kirsten rat sarcoma viral oncogene homolog (KRAS) is the most common oncogene alteration in pancreatic ductal adenocarcinoma, and KRAS glycine to cystine substitution at codon 12 (G12C) mutations (KRAS G12Cmut) are observed in 1%-2%. Several inhibitors of KRAS G12C have recently demonstrated promise in solid tumors, including pancreatic cancer. Little is known regarding clinical, genomics, and outcome data of this population., Methods: Patients with pancreatic cancer and KRAS G12Cmut were identified at Memorial Sloan Kettering Cancer Center and via the American Association of Cancer Research Project Genomics, Evidence, Neoplasia, Information, Exchange database. Clinical, treatment, genomic, and outcomes data were analyzed. A cohort of patients at Memorial Sloan Kettering Cancer Center with non-G12C KRAS pancreatic cancer was included for comparison., Results: Among 3571 patients with pancreatic ductal adenocarcinoma, 39 (1.1%) with KRAS G12Cmut were identified. Median age was 67 years, and 56% were female. Median body mass index was 29.2 kg/m2, and 67% had a smoking history. Median overall survival was 13 months (95% CI: 9.4 months, not reached) for stage IV and 26 months (95% CI: 23 months, not reached) for stage I-III. Complete genomic data (via American Association of Cancer Research Project Genomics, Evidence, Neoplasia, Information, Exchange database) was available for 74 patients. Most common co-alterations included TP53 (73%), CDKN2A (33%), SMAD4 (28%), and ARID1A (21%). Compared with a large cohort (n = 2931) of non-G12C KRAS-mutated pancreatic ductal adenocarcinoma, ARID1A co-mutations were more frequent in KRAS G12Cmut (P < .05). Overall survival did not differ between KRAS G12Cmut and non-G12C KRAS pancreatic ductal adenocarcinoma. Germline pathogenic variants were identified in 17% of patients; 2 patients received KRAS G12C-directed therapy., Conclusion: Pancreatic cancer and KRAS G12Cmut may be associated with a distinct clinical phenotype. Genomic features are similar to non-G12C KRAS-mutated pancreatic cancer, although enrichment of ARID1A co-mutations was observed. Targeting of KRAS G12C in pancreatic cancer provides a precedent for broader KRAS targeting in pancreatic cancer., (© The Author(s) 2024. Published by Oxford University Press. All rights reserved. For permissions, please email: journals.permissions@oup.com.)
- Published
- 2024
- Full Text
- View/download PDF
132. SWI/SNF Complex-Deficient Undifferentiated Carcinoma of the Pancreas: Clinicopathologic and Genomic Analysis.
- Author
-
Yavas A, Ozcan K, Adsay NV, Balci S, Tarcan ZC, Hechtman JF, Luchini C, Scarpa A, Lawlor RT, Mafficini A, Reid MD, Xue Y, Yang Z, Haye K, Bellizzi AM, Vanoli A, Benhamida J, Balachandran V, Jarnagin W, Park W, O'Reilly EM, Klimstra DS, and Basturk O
- Abstract
Inactivating alterations in the SWItch/Sucrose NonFermentable (SWI/SNF) Chromatin Remodeling Complex subunits have been described in multiple tumor types. Recent studies focused on SMARC subunits of this complex to understand their relationship with tumor characteristics and therapeutic opportunities. To date, pancreatic cancer with these alterations has not been well studied, although isolated cases of undifferentiated carcinomas have been reported. Herein, we screened 59 pancreatic undifferentiated carcinomas for alterations in SWI/SNF complex-related (SMARCB1 [BAF47/INI1], SMARCA4 [BRG1], SMARCA2 [BRM]) proteins and/or genes using immunohistochemistry and/or next-generation sequencing. Cases with alterations in SWI/SNF complex-related proteins/genes were compared with cases without alterations, as well as with 96 conventional pancreatic ductal adenocarcinomas (PDAC). In all tumor groups, mismatch repair and PD-L1 protein expression were also evaluated. Thirty of 59 (51%) undifferentiated carcinomas had a loss of SWI/SNF complex-related protein expression or gene alteration. Twenty-seven of 30 (90%) SWI-/SNF-deficient undifferentiated carcinomas had rhabdoid morphology (vs 9/29 [31%] SWI-/SNF-retained undifferentiated carcinomas; P < .001) and all expressed cytokeratin, at least focally. Immunohistochemically, SMARCB1 protein expression was absent in 16/30 (53%) cases, SMARCA2 in 4/30 (13%), and SMARCA4 in 4/30 (13%); both SMARCB1 and SMARCA2 protein expressions were absent in 1/30 (3%). Five of 8 (62.5%) SWI-/SNF-deficient undifferentiated carcinomas that displayed loss of SMARCB1 protein expression by immunohistochemistry were found to have corresponding SMARCB1 deletions by next-generation sequencing. Analysis of canonical driver mutations for PDAC in these cases showed KRAS (2/5) and TP53 (2/5) abnormalities. Median combined positive score for PD-L1 (E1L3N) was significantly higher in the undifferentiated carcinomas with/without SWI/SNF deficiency compared with the conventional PDACs (P < .001). SWI-/SNF-deficient undifferentiated carcinomas were larger (P < .001) and occurred in younger patients (P < .001). Patients with SWI-/SNF-deficient undifferentiated carcinoma had worse overall survival compared with patients with SWI-/SNF-retained undifferentiated carcinoma (P = .004) and PDAC (P < .001). Our findings demonstrate that SWI-/SNF-deficient pancreatic undifferentiated carcinomas are frequently characterized by rhabdoid morphology, exhibit highly aggressive behavior, and have a negative prognostic impact. The ones with SMARCB1 deletions appear to be frequently KRAS wild type. Innovative developmental therapeutic strategies targeting this genomic basis of the SWI/SNF complex and the therapeutic implications of EZH2 inhibition (NCT03213665), SMARCA2 degrader (NCT05639751), or immunotherapy are currently under investigation., (Copyright © 2024 United States & Canadian Academy of Pathology. Published by Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
133. Extrahepatic Cholangiocarcinoma: Genomic Variables Associated With Anatomic Location and Outcome.
- Author
-
Preston WA, Drill E, Boerner T, Gelfer R, Harding JJ, O'Reilly EM, Cercek A, Abou-Alfa G, Park W, Balachandran VP, Drebin J, Soares KC, Wei A, Kingham TP, D'Angelica MI, and Jarnagin WR
- Subjects
- Humans, Male, Female, Middle Aged, Aged, Genomics, Adult, Aged, 80 and over, Bile Duct Neoplasms genetics, Bile Duct Neoplasms pathology, Bile Duct Neoplasms mortality, Cholangiocarcinoma genetics, Cholangiocarcinoma mortality, Cholangiocarcinoma pathology, Cholangiocarcinoma surgery
- Abstract
Purpose: This study aimed to define genomic differences between perihilar cholangiocarcinoma (PCA) and distal cholangiocarcinoma (DCA) and identify genomic determinants of survival., Materials and Methods: Consecutive patients with ECA with tissue for targeted next-generation sequencing were analyzed, stratified by anatomic site (PCA/DCA), disease extent, and treatment. Associations between genomic alterations, clinicopathologic features, and outcomes were analyzed using Cox proportional hazards regression to compare survival., Results: In total, 224 patients diagnosed between 2004 and 2022 (n = 127 PCA; n = 97 DCA) met inclusion criteria. The median survival was 29 months (43 after resection and 17 from diagnosis for unresectable disease). Compared with PCA, DCA was enriched in TP53alt (alterations; 69% v 33%; Q < 0.01), epigenetic pathway alterations (45% v 29%; Q = 0.041), and had more total altered pathways (median 3 v 2; Q < 0.01). KRASalt frequency was similar between PCA (36%) and DCA (37%); however, DCA was enriched in KRAS G12D (19% v 9%; P = .002 ). No other clinicopathologic or genomic variables distinguished subtypes. In resected patients, no genomic alterations were associated with outcome. However, in unresectable patients, CDKN2Aalt (hazard ratio [HR], 2.59 [1.48 to 4.52]) and APCalt (HR, 5.11 [1.96 to 13.3]) were associated with reduced survival. For the entire cohort, irresectability (HR, 3.13 [2.25 to 4.36]), CDKN2Aalt (HR, 1.80 [1.80 to 2.68]), and APCalt (HR, 2.00 [1.04 to 3.87]) were associated with poor survival., Conclusion: CDKN2Aalt and APCalt were associated with poor survival in ECA, primarily in advanced disease. As PCA and DCA were genetically similar, coanalysis of PCA and DCA in future genomic studies is reasonable.
- Published
- 2024
- Full Text
- View/download PDF
134. Morbidity and mortality in patients with stage IV pancreatic adenocarcinoma and acute cholangitis: Outcomes and risk prognostication.
- Author
-
Singh I, Chou JF, Capanu M, Park J, Yu KH, Varghese AM, Park W, Zervoudakis A, Keane F, Rolston VS, Gerdes H, Wei AC, Shah P, Covey A, Schattner M, and O'Reilly EM
- Subjects
- Humans, Male, Female, Aged, Retrospective Studies, Middle Aged, Prognosis, Neoplasm Staging, Carcinoma, Pancreatic Ductal mortality, Carcinoma, Pancreatic Ductal complications, Carcinoma, Pancreatic Ductal pathology, Aged, 80 and over, Adenocarcinoma mortality, Adenocarcinoma complications, Adenocarcinoma pathology, Acute Disease, Risk Factors, Cholangitis complications, Cholangitis mortality, Pancreatic Neoplasms mortality, Pancreatic Neoplasms complications, Pancreatic Neoplasms pathology
- Abstract
Background: Acute cholangitis (AC) is a common complication of pancreatic ductal adenocarcinoma (PDAC). Herein, we evaluated outcomes after the first AC episode and predictors of mortality and AC recurrence in patients with stage IV PDAC., Methods: We conducted a single-center, retrospective observational study using institutional databases. Clinical data and outcomes for patients with stage IV PDAC and at least one documented episode of AC, were assessed. Overall survival (OS) was estimated using the Kaplan-Meier method, and Cox regression model was employed to identify predictors of AC recurrence and mortality., Results: One hundred and twenty-four patients with stage IV PDAC and AC identified between January 01, 2014 and October 31, 2020 were included. Median OS after first episode of AC was 4.1 months (95 % CI, 4.0-5.5), and 30-day, 6, and 12-month survival was 86.2 % (95 % CI, 80.3-92.5), 37 % (95 % CI, 29.3-46.6 %) and 18.9 % (95 % CI, 13.1-27.3 %), respectively. Primary tumor in pancreatic body/tail (HR 2.29, 95 % CI: 1.26 to 4.18, p = 0.011), concomitant metastases to liver and other sites (HR 1.96, 95 % CI: 1.16 to 3.31, p = 0.003) and grade 3 AC (HR 2.26, 95 % CI: 1.45 to 3.52, p < 0.001), predicted worse outcomes. Intensive care unit admission, sepsis, systemic therapy, treatment regimen, and time to intervention did not predict survival or risk of recurrence of AC., Conclusions: AC confers significant morbidity and mortality in advanced PDAC. Worse outcomes are associated with higher grade AC, primary tumor location in pancreatic body/tail, and metastases to liver and other sites., Competing Interests: Declaration of competing interest IS has no conflict of interest. MS ∗∗∗, JC ∗∗∗, MC∗∗∗, JP∗∗, KY∗∗, AV∗∗, WP∗∗, VR∗∗, HS∗∗; EOR: Research Funding to institution: Genentech/Roche, BioNTech, AstraZeneca, Arcus, Elicio, Parker Institute, NIH/NCI, Digestive Care, Break Through Cancer. Consulting/DSMB: Arcus, Alligator, Agenus, BioNTech, Ipsen, Merck, Moma Therapeutics, Novartis, Syros, Leap Therapeutics, Astellas, BMS, Fibrogen, Revolution Medicine, Merus. Agios (spouse), Genentech-Roche (spouse), Eisai (spouse) Servier (Spouse)., (Copyright © 2024 The Authors. Published by Elsevier B.V. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
135. Salvage Ablative Radiotherapy for Isolated Local Recurrence of Pancreatic Adenocarcinoma following Definitive Surgery.
- Author
-
Dee EC, Ng VC, O'Reilly EM, Wei AC, Lobaugh SM, Varghese AM, Zinovoy M, Romesser PB, Wu AJ, Hajj C, Cuaron JJ, Khalil DN, Park W, Yu KH, Zhang Z, Drebin JA, Jarnagin WR, Crane CH, and Reyngold M
- Abstract
Introduction: The rate of isolated locoregional recurrence after surgery for pancreatic adenocarcinoma (PDAC) approaches 25%. Ablative radiation therapy (A-RT) has improved outcomes for locally advanced disease in the primary setting. We sought to evaluate the outcomes of salvage A-RT for isolated locoregional recurrence and examine the relationship between subsequent patterns of failure, radiation dose, and treatment volume. Methods : We conducted a retrospective analysis of all consecutive participants who underwent A-RT for an isolated locoregional recurrence of PDAC after prior surgery at our institution between 2016 and 2021. Treatment consisted of ablative dose (BED10 98-100 Gy) to the gross disease with an additional prophylactic low dose (BED10 < 50 Gy), with the elective volume covering a 1.5 cm isotropic expansion around the gross disease and the circumference of the involved vessels. Local and locoregional failure (LF and LRF, respectively) estimated by the cumulative incidence function with competing risks, distant metastasis-free and overall survival (DMFS and OS, respectively) estimated by the Kaplan-Meier method, and toxicities scored by CTCAE v5.0 are reported. Location of recurrence was mapped to the dose region on the initial radiation plan. Results : Among 65 participants (of whom two had two A-RT courses), the median age was 67 (range 37-87) years, 36 (55%) were male, and 53 (82%) had undergone pancreaticoduodenectomy with a median disease-free interval to locoregional recurrence of 16 (range, 6-71) months. Twenty-seven participants (42%) received chemotherapy prior to A-RT. With a median follow-up of 35 months (95%CI, 26-56 months) from diagnosis of recurrence, 24-month OS and DMFS were 57% (95%CI, 46-72%) and 22% (95%CI, 14-37%), respectively, while 24-month cumulative incidence of in-field LF and total LRF were 28% (95%CI, 17-40%) and 36% (95%CI 24-48%), respectively. First failure after A-RT was distant in 35 patients (53.8%), locoregional in 12 patients (18.5%), and synchronous distant and locoregional in 10 patients (15.4%). Most locoregional failures occurred in elective low-dose volumes. Acute and chronic grade 3-4 toxicities were noted in 1 (1.5%) and 5 patients (7.5%), respectively. Conclusions : Salvage A-RT achieves favorable OS and local control outcomes in participants with an isolated locoregional recurrence of PDAC after surgical resection. Consideration should be given to extending high-dose fields to include adjacent segments of at-risk vessels beyond direct contact with the gross disease.
- Published
- 2024
- Full Text
- View/download PDF
136. Genomic Profiling Reveals Germline Predisposition and Homologous Recombination Deficiency in Pancreatic Acinar Cell Carcinoma.
- Author
-
Mandelker D, Marra A, Zheng-Lin B, Selenica P, Blanco-Heredia J, Zhu Y, Gazzo A, Wong D, Yelskaya Z, Rai V, Somar J, Ostafi S, Mehta N, Yang C, Li Y, Brown DN, da Silva EM, Pei X, Linkov I, Terraf P, Misyura M, Ceyhan-Birsoy O, Ladanyi M, Berger M, Pareja F, Stadler Z, Offit K, Riaz N, Park W, Chou J, Capanu M, Koehler M, Rosen E, O'Reilly EM, and Reis-Filho JS
- Subjects
- Male, Humans, BRCA2 Protein genetics, BRCA1 Protein genetics, Germ-Line Mutation, Genetic Predisposition to Disease, Homologous Recombination, Genomics, Pancreatic Neoplasms, Carcinoma, Acinar Cell genetics, Pancreatic Neoplasms genetics
- Abstract
Purpose: To determine the genetic predisposition underlying pancreatic acinar cell carcinoma (PACC) and characterize its genomic features., Methods: Both somatic and germline analyses were performed using an Food and Drug Administration-authorized matched tumor/normal sequencing assay on a clinical cohort of 28,780 patients with cancer, 49 of whom were diagnosed with PACC. For a subset of PACCs, whole-genome sequencing (WGS; n = 12) and RNA sequencing (n = 6) were performed., Results: Eighteen of 49 (36.7%) PACCs harbored germline pathogenic variants in homologous recombination (HR) and DNA damage response (DDR) genes, including BRCA1 (n = 1), BRCA2 (n = 12), PALB2 (n = 2), ATM (n = 2), and CHEK2 (n = 1). Thirty-one PACCs displayed pure, and 18 PACCs harbored mixed acinar cell histology. Fifteen of 31 (48%) pure PACCs harbored a germline pathogenic variant affecting HR-/DDR-related genes. BRCA2 germline pathogenic variants (11 of 31, 35%) were significantly more frequent in pure PACCs than in pancreatic adenocarcinoma (86 of 2,739, 3.1%; P < .001), high-grade serous ovarian carcinoma (67 of 1,318, 5.1%; P < .001), prostate cancer (116 of 3,401, 3.4%; P < .001), and breast cancer (79 of 3,196, 2.5%; P < .001). Genomic features of HR deficiency (HRD) were detected in 7 of 12 PACCs undergoing WGS, including 100% (n = 6) of PACCs with germline HR-related pathogenic mutations and 1 of 6 PACCs lacking known pathogenic alterations in HR-related genes. Exploratory analyses revealed that in PACCs, the repertoire of somatic driver genetic alterations and the load of neoantigens with high binding affinity varied according to the presence of germline pathogenic alterations affecting HR-/DDR-related genes and/or HRD., Conclusion: In a large pan-cancer cohort, PACC was identified as the cancer type with the highest prevalence of both BRCA2 germline pathogenic variants and genomic features of HRD, suggesting that PACC should be considered as part of the spectrum of BRCA -related malignancies.
- Published
- 2023
- Full Text
- View/download PDF
137. Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer.
- Author
-
Rojas LA, Sethna Z, Soares KC, Olcese C, Pang N, Patterson E, Lihm J, Ceglia N, Guasp P, Chu A, Yu R, Chandra AK, Waters T, Ruan J, Amisaki M, Zebboudj A, Odgerel Z, Payne G, Derhovanessian E, Müller F, Rhee I, Yadav M, Dobrin A, Sadelain M, Łuksza M, Cohen N, Tang L, Basturk O, Gönen M, Katz S, Do RK, Epstein AS, Momtaz P, Park W, Sugarman R, Varghese AM, Won E, Desai A, Wei AC, D'Angelica MI, Kingham TP, Mellman I, Merghoub T, Wolchok JD, Sahin U, Türeci Ö, Greenbaum BD, Jarnagin WR, Drebin J, O'Reilly EM, and Balachandran VP
- Subjects
- Humans, Adjuvants, Immunologic therapeutic use, CD8-Positive T-Lymphocytes cytology, CD8-Positive T-Lymphocytes immunology, Immunotherapy, mRNA Vaccines, Antigens, Neoplasm immunology, Cancer Vaccines immunology, Carcinoma, Pancreatic Ductal genetics, Carcinoma, Pancreatic Ductal immunology, Carcinoma, Pancreatic Ductal therapy, Lymphocyte Activation immunology, Pancreatic Neoplasms genetics, Pancreatic Neoplasms immunology, Pancreatic Neoplasms therapy, T-Lymphocytes cytology, T-Lymphocytes immunology
- Abstract
Pancreatic ductal adenocarcinoma (PDAC) is lethal in 88% of patients
1 , yet harbours mutation-derived T cell neoantigens that are suitable for vaccines2,3 . Here in a phase I trial of adjuvant autogene cevumeran, an individualized neoantigen vaccine based on uridine mRNA-lipoplex nanoparticles, we synthesized mRNA neoantigen vaccines in real time from surgically resected PDAC tumours. After surgery, we sequentially administered atezolizumab (an anti-PD-L1 immunotherapy), autogene cevumeran (a maximum of 20 neoantigens per patient) and a modified version of a four-drug chemotherapy regimen (mFOLFIRINOX, comprising folinic acid, fluorouracil, irinotecan and oxaliplatin). The end points included vaccine-induced neoantigen-specific T cells by high-threshold assays, 18-month recurrence-free survival and oncologic feasibility. We treated 16 patients with atezolizumab and autogene cevumeran, then 15 patients with mFOLFIRINOX. Autogene cevumeran was administered within 3 days of benchmarked times, was tolerable and induced de novo high-magnitude neoantigen-specific T cells in 8 out of 16 patients, with half targeting more than one vaccine neoantigen. Using a new mathematical strategy to track T cell clones (CloneTrack) and functional assays, we found that vaccine-expanded T cells comprised up to 10% of all blood T cells, re-expanded with a vaccine booster and included long-lived polyfunctional neoantigen-specific effector CD8+ T cells. At 18-month median follow-up, patients with vaccine-expanded T cells (responders) had a longer median recurrence-free survival (not reached) compared with patients without vaccine-expanded T cells (non-responders; 13.4 months, P = 0.003). Differences in the immune fitness of the patients did not confound this correlation, as responders and non-responders mounted equivalent immunity to a concurrent unrelated mRNA vaccine against SARS-CoV-2. Thus, adjuvant atezolizumab, autogene cevumeran and mFOLFIRINOX induces substantial T cell activity that may correlate with delayed PDAC recurrence., (© 2023. The Author(s).)- Published
- 2023
- Full Text
- View/download PDF
138. Dramatic, durable response to therapy in gBRCA2-mutated pancreas neuroendocrine carcinoma: opportunity and challenge.
- Author
-
Keane F, Bajwa R, Selenica P, Park W, Roehrl MH, Reis-Filho JS, Mandelker D, and O'Reilly EM
- Abstract
Poorly differentiated pancreatic neuroendocrine tumors (PDNEC), are a subtype of pancreatic cancer encompassing both small cell and large cell neuroendocrine carcinoma subtypes, and are characterized as distinct in terms of biology and prognosis compared to the more common pancreatic adenocarcinoma. Until recently, there has been a paucity of data on the genomic features of this cancer type. We describe a male patient diagnosed with PDNEC and extensive metastatic disease in the liver at diagnosis. Genomic analysis demonstrated a germline pathogenic variant in BRCA2 with somatic loss-of-heterozygosity of the BRCA2 wild-type allele. Following a favorable response to platinum-based chemotherapy (and the addition of immunotherapy), the patient received maintenance therapy with olaparib, which resulted in a further reduction on follow-up imaging (Fig. 1). After seventeen months of systemic control with olaparib, the patient developed symptomatic central nervous system metastases, which harboured a BRCA2 reversion mutation. No other sites of disease progression were observed. Herein, we report an exceptional outcome through the incorporation of a personalized management approach for a patient with a pancreatic PDNEC, guided by comprehensive genomic sequencing., (© 2023. The Author(s).)
- Published
- 2023
- Full Text
- View/download PDF
139. Stereotactic ablative radiation for pancreatic cancer on a 1.5 Telsa magnetic resonance-linac system.
- Author
-
Tringale KR, Tyagi N, Marsha Reyngold, Romesser PB, Wu A, O'Reilly EM, Varghese AM, Godoy Scripes P, Khalil DN, Park W, Yu K, and Crane CH
- Abstract
Purpose: Ablative radiation therapy (A-RT) appears to improve outcomes in locally advanced pancreatic cancer (LAPC) yet requires solutions for respiratory and digestive motion. We report outcomes of A-RT for pancreatic cancer using 1.5 T MR-adaptive treatment delivery., Methods: Between March 2020 and July 2021, we treated 30 patients with pancreatic cancer with 50 Gy in 5 fractions (biologically effective dose [BED10] = 100 Gy10) using a novel compression belt workflow and remote planning on the Unity 1.5 T MR linac system. Cumulative incidence of progression was computed from A-RT initiation with death as a competing risk. Overall (OS) and progression-free survival (PFS) were calculated using Kaplan Meier methods., Results: Of 30 patients, most (73 %) were locally advanced, 4 (13 %) were metastatic, 2 (7 %) were medically inoperable, and 2 (7 %) were locally recurrent. Most (73 %) received FOLFIRINOX prior to A-RT. Median follow-up times from diagnosis and A-RT were 17.6 (IQR 15.8-23.1) and 11.5 months (IQR 9.7-16.1), respectively. Cumulative incidences at 1-year of local and distant progression were 19.3 % (95 %CI 6.7-36.8 %) and 47.4 % (95 %CI 26.7-65.6 %), respectively. Median OS from diagnosis and A-RT were not reached. One-year OS from diagnosis and A-RT were 96.4 % (95 %CI 77.2-99.5 %) and 80.0 % (95 %CI 57.3-91.4 %), respectively. Median and 1-year PFS were 10.1 months (95 %CI 4.4-14.4) and 39.7 % (95 %CI 20.3-58.5 %), respectively. No grade 3 + toxicities were observed., Conclusions: A-RT using the 1.5 T Unity MR Linac resulted in promising LC and OS with no severe toxicity in patients with LAPC despite radiosensitive organs adjacent to the target volumes. Longer follow-up is needed to assess long-term outcomes., Competing Interests: The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: K.R.T. reports grant funding from the Radiological Society of North America for an unrelated research study. N.T. discloses provision of services from Elekta, Philips (uncompensated), and Sunnybrook Health Sciences Centre. M.R. is a member of the National Comprehensive Cancer Network Panel on Pancreatic Cancer. P.B.R. reports prior research funding from EMD Serono and has received travel support from Elekta. P.B.R. is supported in part by an NIH/NCI grant (K08CA255574) and an NIH Loan Repayment Program (LRP) award. E.M.O reports provision of services from the American Association for Cancer Research; BioNTech; CytomX Therapeutics; HMP Oncology Learning Network; Imedex, Inc.; Integrity Continuing Education, Inc.; Merck & Co Inc.; National Comprehensive Cancer Network; Paradigm Medical Communications, LLC; Physician’s Education Resource; Polaris Group; Rafael Pharmaceuticals, Inc.; Research to Practice; Shanghai Jo’Ann Medical Technology Co., Ltd; Swedish Orphan Biovitrum; WebMD; and twoXar, Inc. A.M.V. reports provision of services from Bristol-Meyers Squibb, GlaxoSmithKline, Lily Oncology, and Silenseed Ltd. D.N.K. reports intellectual property rights with Merck Sharp & Dohme and PsiOxus Therapeutics Ltd. K.Y. reports provision of services from Ipsen Pharma. C.H.C. reports provision of services from AstraZeneca, Elekta, and Trisalus. C.H.C. has ownership/equity interests in Oncternal Therapeutics, Inc., (© 2022 The Authors.)
- Published
- 2022
- Full Text
- View/download PDF
140. Homologous Recombination Deficiency in Pancreatic Cancer: Poly (ADP-ribose) Polymerase Inhibition, Checkpoint Inhibition, or a Combination of Both?
- Author
-
Keane F, Park W, and O'Reilly EM
- Subjects
- Adenosine Diphosphate, Homologous Recombination genetics, Humans, Ribose, Pancreatic Neoplasms drug therapy, Poly(ADP-ribose) Polymerases
- Published
- 2022
- Full Text
- View/download PDF
141. Targeting DNA damage repair pathways in pancreas cancer.
- Author
-
Crowley F, Park W, and O'Reilly EM
- Subjects
- DNA Damage, DNA Repair genetics, Humans, Poly(ADP-ribose) Polymerase Inhibitors therapeutic use, Carcinoma, Pancreatic Ductal drug therapy, Carcinoma, Pancreatic Ductal genetics, Pancreatic Neoplasms drug therapy, Pancreatic Neoplasms genetics
- Abstract
Pancreas ductal adenocarcinoma (PDAC) is the third most common cause of cancer death in the USA. While other cancers with historically poor prognoses have benefited from new immunotherapies and targeted agents, the 5-year survival rate for PDAC patients has remained static. The accessibility to genomic testing has improved in recent years, and it is now clear that PDAC is a heterogenous disease, with a subset of patients harboring actionable mutations. There are several targeted therapies approved by the Food and Drug administration (FDA) in PDAC: EGFR inhibitor erlotinib (combined with gemcitabine) in unselected patients, TRK inhibitors larotrectinib and entrectinib for patients with NTRK fusion mutation, the PD-1 inhibitor pembrolizumab for mismatch repair-deficient patients, and the poly-ADP-ribose polymerase (PARP) inhibitor olaparib in patients with germline BRCA mutation as a maintenance therapy. DNA damage repair (DDR) is paramount to genomic integrity and cell survival. The defective repair of DNA damage is one of the hallmarks of cancer, and abnormalities in DDR pathways are closely linked with the development of malignancies and upregulation of these pathways linked with resistance to treatment. The prevalence of somatic and germline mutations in DDR pathways in metastatic PDAC is reported to be approximately 15-25%. Patients with DDR gene alterations benefit from a personalized approach to treatment. Recently, the POLO trial demonstrated a progression-free survival (PFS) benefit in metastatic PDAC patients with a germline BRCA1/2 mutation treated with maintenance olaparib following platinum-based induction chemotherapy. This was the first phase 3 randomized trial to establish a biomarker-driven approach in the treatment of PDAC and establishes a precedent for maintenance therapy in PDAC. The review herein aims to outline the current treatment landscape for PDAC patients with DDR gene-mutated tumors, highlight novel therapeutic approaches focused on surmounting tumor resistance, and explore new strategies which may lead to an expansion in the number of patients who benefit from these targeted treatments., (© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.)
- Published
- 2021
- Full Text
- View/download PDF
142. Leptomeningeal disease in pancreas ductal adenocarcinoma: A manifestation of longevity.
- Author
-
O'Connor CA, Park JS, Kaley T, Kezlarian B, Edelweiss M, Yang TJ, Park W, Reidy D, Varghese AM, Yu KH, and O'Reilly EM
- Subjects
- Aged, Carcinoma, Pancreatic Ductal diagnosis, Carcinoma, Pancreatic Ductal therapy, Combined Modality Therapy, Databases, Factual, Fatal Outcome, Female, Humans, Lung Neoplasms mortality, Lung Neoplasms secondary, Lung Neoplasms therapy, Male, Meningeal Neoplasms diagnosis, Meningeal Neoplasms therapy, Middle Aged, Pancreatic Neoplasms therapy, Prognosis, Retrospective Studies, Carcinoma, Pancreatic Ductal secondary, Meningeal Neoplasms secondary, Pancreatic Neoplasms pathology
- Abstract
Background: /Objectives: Pancreatic adenocarcinoma (PDAC) metastatic to the leptomeninges is a rare and lethal event. Leptomeningeal disease (LMD) research is limited in PDAC, and insights into clinical descriptors, possible disease predictors, and treatment strategies is necessitated., Methods: Memorial Sloan Kettering databases were queried with Institutional Review Board approval to identify patients with LMD and PDAC treated between January 2000 and June 2020. Medical record review was used to abstract clinical, genomic, pathologic, and radiographic data. Overall survival was calculated from date of PDAC diagnosis to date of death. Previously published literature on LMD from PDAC was reviewed., Results: Four patients with LMD from PDAC were identified, two males and two females. Age at diagnosis ranged from 57 to 68 years. All four patients had predominant lung metastasis and a relatively low burden of intra-abdominal disease. Somatic testing indicated alterations typical of PDAC and no PDAC defining pathogenic germline mutations were identified. An extended clinical course prior to LMD diagnosis was observed in all patients, ranging from 16 to 148 months. Upon diagnosis of LMD, three patients elected for supportive care and one patient received a limited course of craniospinal radiation. The median survival following diagnosis of LMD was 1.6 months (range 0.5-2.8 months)., Conclusions: LMD from PDAC is a rare occurrence that may be more frequent in patients with lung metastasis and/or a more indolent clinical course. Following diagnosis of LMD, prognosis is poor, and survival is short. New treatment strategies for this manifestation of PDAC are needed., Competing Interests: Declaration of competing interest EOR Research Funding to MSK: Genentech/Roche, Celgene/BMS, BioNTech, BioAtla, AstraZeneca, Arcus. EOR Consulting Role: Cytomx Therapeutics (DSMB), Rafael Therapeutics (DSMB), Sobi, Silenseed, Molecular Templates, Boehringer Ingelheim, BioNTech, Ipsen (+spouse), Polaris (+spouse), Merck (+spouse), AstraZeneca (+spouse), Bayer (spouse), Genentech/Roche (spouse), Celgene/BMS (spouse), Eisai (spouse). No other authors have disclosures., (Copyright © 2021 IAP and EPC. Published by Elsevier B.V. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
143. Clinical and Immunological Implications of Frameshift Mutations in Lung Cancer.
- Author
-
Chae YK, Viveiros P, Lopes G, Sukhadia B, Sheikh MM, Saravia D, Florou V, Sokol ES, Frampton GM, Chalmers ZR, Ali SM, Ross JS, Chang S, Wang S, Chiec L, Rahbari A, Mohindra N, Villaflor V, Shin SH, Oh M, Anker J, Park LC, Wang V, Chuang J, and Park W
- Subjects
- Adenocarcinoma of Lung drug therapy, Adenocarcinoma of Lung genetics, Adenocarcinoma of Lung immunology, Adenocarcinoma of Lung pathology, Biomarkers, Tumor genetics, Biomarkers, Tumor immunology, CD8-Positive T-Lymphocytes, Carcinoma, Squamous Cell drug therapy, Carcinoma, Squamous Cell genetics, Carcinoma, Squamous Cell immunology, Carcinoma, Squamous Cell pathology, Female, Follow-Up Studies, Humans, Immunotherapy, Lung Neoplasms drug therapy, Lung Neoplasms genetics, Male, Middle Aged, Prognosis, Retrospective Studies, Survival Rate, Antigens, Neoplasm immunology, Antineoplastic Agents, Immunological therapeutic use, Biomarkers, Tumor analysis, Frameshift Mutation, INDEL Mutation, Lung Neoplasms immunology, Lung Neoplasms pathology
- Abstract
Introduction: Presently, programmed death ligand 1 is the most commonly used biomarker to predict response to immune checkpoint inhibitors (ICIs) in NSCLC. Owing to its several limitations, there is continuous search for more precise and reliable markers. Frameshift mutations by insertion or deletion (fsindels) are suggested to induce more immunogenic tumor-specific neoantigens, conferring better response to ICIs. Positive correlation of fsindels with ICI response has been studied in melanoma and renal cell carcinoma. We investigated the implication of fsindels in the clinical outcomes and immune landscape of patients with NSCLC treated with ICIs., Methods: We utilized The Cancer Genome Atlas data set to analyze tumor mutational burden, neoantigen burden, and immune landscape in relation to fsindel status. In addition, utilizing the clinical data from 122 patients treated with ICIs, we evaluated the influence of fsindels on disease response rates and survival outcomes., Results: A positive correlation between fsindel burden and tumor mutational burden and activated CD4/CD8 T-cell infiltration was shown. Presence of fsindels was also associated with significant prolongation of progression-free survival in patients treated with ICIs (median 6.2 versus 2.7 months [p = 0.01]). In addition, significant differences in the overall response rates (26% versus 12% [p = 0.04]) and disease control rates (68% versus 48% [p = 0.02]) were observed in patients with fsindels., Conclusion: Our findings suggest that fsindels may have a predictive role for ICI response in NSCLC., (Copyright © 2019 International Association for the Study of Lung Cancer. Published by Elsevier Inc. All rights reserved.)
- Published
- 2019
- Full Text
- View/download PDF
144. Correction to: Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshop.
- Author
-
Bedognetti D, Ceccarelli M, Galluzzi L, Lu R, Palucka K, Samayoa J, Spranger S, Warren S, Wong KK, Ziv E, Chowell D, Coussens LM, De Carvalho DD, DeNardo DG, Galon J, Kaufman HL, Kirchhoff T, Lotze MT, Luke JJ, Minn AJ, Politi K, Shultz LD, Simon R, Thórsson V, Weidhaas JB, Ascierto ML, Ascierto PA, Barnes JM, Barsan V, Bommareddy PK, Bot A, Church SE, Ciliberto G, De Maria A, Draganov D, Ho WS, McGee HM, Monette A, Murphy JF, Nisticò P, Park W, Patel M, Quigley M, Radvanyi L, Raftopoulos H, Rudqvist NP, Snyder A, Sweis RF, Valpione S, Zappasodi R, Butterfield LH, Disis ML, Fox BA, Cesano A, and Marincola FM
- Abstract
Following publication of the original article [1], the author reported that an author name, Roberta Zappasodi, was missed in the authorship list.
- Published
- 2019
- Full Text
- View/download PDF
145. Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshop.
- Author
-
Bedognetti D, Ceccarelli M, Galluzzi L, Lu R, Palucka K, Samayoa J, Spranger S, Warren S, Wong KK, Ziv E, Chowell D, Coussens LM, De Carvalho DD, DeNardo DG, Galon J, Kaufman HL, Kirchhoff T, Lotze MT, Luke JJ, Minn AJ, Politi K, Shultz LD, Simon R, Thórsson V, Weidhaas JB, Ascierto ML, Ascierto PA, Barnes JM, Barsan V, Bommareddy PK, Bot A, Church SE, Ciliberto G, De Maria A, Draganov D, Ho WS, McGee HM, Monette A, Murphy JF, Nisticò P, Park W, Patel M, Quigley M, Radvanyi L, Raftopoulos H, Rudqvist NP, Snyder A, Sweis RF, Valpione S, Zappasodi R, Butterfield LH, Disis ML, Fox BA, Cesano A, and Marincola FM
- Subjects
- Advisory Committees, Animals, Biomarkers, Tumor genetics, Biomarkers, Tumor immunology, Congresses as Topic, Disease Models, Animal, Humans, Medical Oncology organization & administration, Neoplasms genetics, Neoplasms immunology, Societies, Medical organization & administration, Treatment Outcome, Tumor Microenvironment genetics, Immunotherapy, Neoplasms therapy, Tumor Microenvironment immunology
- Abstract
Tumor immunology has changed the landscape of cancer treatment. Yet, not all patients benefit as cancer immune responsiveness (CIR) remains a limitation in a considerable proportion of cases. The multifactorial determinants of CIR include the genetic makeup of the patient, the genomic instability central to cancer development, the evolutionary emergence of cancer phenotypes under the influence of immune editing, and external modifiers such as demographics, environment, treatment potency, co-morbidities and cancer-independent alterations including immune homeostasis and polymorphisms in the major and minor histocompatibility molecules, cytokines, and chemokines. Based on the premise that cancer is fundamentally a disorder of the genes arising within a cell biologic process, whose deviations from normality determine the rules of engagement with the host's response, the Society for Immunotherapy of Cancer (SITC) convened a task force of experts from various disciplines including, immunology, oncology, biophysics, structural biology, molecular and cellular biology, genetics, and bioinformatics to address the complexity of CIR from a holistic view. The task force was launched by a workshop held in San Francisco on May 14-15, 2018 aimed at two preeminent goals: 1) to identify the fundamental questions related to CIR and 2) to create an interactive community of experts that could guide scientific and research priorities by forming a logical progression supported by multiple perspectives to uncover mechanisms of CIR. This workshop was a first step toward a second meeting where the focus would be to address the actionability of some of the questions identified by working groups. In this event, five working groups aimed at defining a path to test hypotheses according to their relevance to human cancer and identifying experimental models closest to human biology, which include: 1) Germline-Genetic, 2) Somatic-Genetic and 3) Genomic-Transcriptional contributions to CIR, 4) Determinant(s) of Immunogenic Cell Death that modulate CIR, and 5) Experimental Models that best represent CIR and its conversion to an immune responsive state. This manuscript summarizes the contributions from each group and should be considered as a first milestone in the path toward a more contemporary understanding of CIR. We appreciate that this effort is far from comprehensive and that other relevant aspects related to CIR such as the microbiome, the individual's recombined T cell and B cell receptors, and the metabolic status of cancer and immune cells were not fully included. These and other important factors will be included in future activities of the taskforce. The taskforce will focus on prioritization and specific actionable approach to answer the identified questions and implementing the collaborations in the follow-up workshop, which will be held in Houston on September 4-5, 2019.
- Published
- 2019
- Full Text
- View/download PDF
146. Antiangiogenic effects of ganetespib in colorectal cancer mediated through inhibition of HIF-1α and STAT-3.
- Author
-
Nagaraju GP, Park W, Wen J, Mahaseth H, Landry J, Farris AB, Willingham F, Sullivan PS, Proia DA, El-Hariry I, Taliaferro-Smith L, Diaz R, and El-Rayes BF
- Subjects
- Adenocarcinoma drug therapy, Adenocarcinoma pathology, Angiogenesis Inhibitors therapeutic use, Animals, Antineoplastic Agents therapeutic use, Cell Line, Tumor, Chick Embryo, Chorioallantoic Membrane blood supply, Collagen, Colorectal Neoplasms pathology, Down-Regulation, Drug Combinations, Female, Fibroblast Growth Factor 2 antagonists & inhibitors, Fibroblast Growth Factor 2 biosynthesis, Fibroblast Growth Factor 2 genetics, Gene Expression Regulation, Neoplastic, Gene Knockdown Techniques, HEK293 Cells, HSP90 Heat-Shock Proteins physiology, Human Umbilical Vein Endothelial Cells, Humans, Hypoxia-Inducible Factor 1, alpha Subunit genetics, Hypoxia-Inducible Factor 1, alpha Subunit physiology, Laminin, Mice, Nude, Platelet-Derived Growth Factor antagonists & inhibitors, Platelet-Derived Growth Factor biosynthesis, Platelet-Derived Growth Factor genetics, Proteoglycans, RNA, Messenger biosynthesis, Rectal Neoplasms drug therapy, Rectal Neoplasms genetics, Rectal Neoplasms pathology, Ribonuclease, Pancreatic antagonists & inhibitors, Ribonuclease, Pancreatic biosynthesis, Ribonuclease, Pancreatic genetics, STAT3 Transcription Factor genetics, STAT3 Transcription Factor physiology, Specific Pathogen-Free Organisms, Transforming Growth Factor beta1 antagonists & inhibitors, Transforming Growth Factor beta1 biosynthesis, Transforming Growth Factor beta1 genetics, Triazoles therapeutic use, Vascular Endothelial Growth Factor A antagonists & inhibitors, Vascular Endothelial Growth Factor A biosynthesis, Vascular Endothelial Growth Factor A genetics, Vesicular Transport Proteins antagonists & inhibitors, Vesicular Transport Proteins biosynthesis, Vesicular Transport Proteins genetics, Xenograft Model Antitumor Assays, Adenocarcinoma blood supply, Angiogenesis Inhibitors pharmacology, Antineoplastic Agents pharmacology, Colorectal Neoplasms blood supply, HSP90 Heat-Shock Proteins antagonists & inhibitors, Hypoxia-Inducible Factor 1, alpha Subunit antagonists & inhibitors, STAT3 Transcription Factor antagonists & inhibitors, Triazoles pharmacology
- Abstract
Hypoxia-inducible factors (HIFs) and STAT-3 play essential roles in angiogenesis. HIF-1α and STAT-3 are clients of the heat shock protein 90 (HSP90). We hypothesized that ganetespib, a potent HSP90 inhibitor, would disrupt angiogenesis in colorectal cancer (CRC) through inhibition of HIF-1α and STAT-3. CRC cell lines (HCT116 and HT29) were used in all the experiments. Egg CAM and HUVEC assays revealed decreased angiogenesis in ganetespib treated cell lines. Ganetespib inhibited matrigel plug vascularization and tumor growth of xenografts. Significant inhibition of PDGFA, FGF2, Ang-1, Ang-2, TGFβ1, VEGF, HIF-1α and STAT-3 expression was observed in both cell lines treated ganetespib. HIF-1α overexpression resulted in the increase VEGF and STAT-3 expression and this was inhibited by ganetespib. HIF-1α knockdown inhibited VEGF and STAT-3 expression. STAT-3 knockdown inhibited VEGF but not HIF-1α expression. HSP90, STAT-3 and VEGF expression was significantly higher in CRC compared to adjacent normal tissue. Significant downregulation of PDGFA, FGF2, Ang-1, Ang-2, TGFβ1, VEGF, STAT-3 and HIF-1α mRNA was observed in the post ganetespib treatment tumor samples from patients with rectal cancer. These results collectively suggest that inhibition of HSP90 is a promising antiangiogenic strategy in CRC. HSP90 angiogenic effects are mediated through HIF-1α and STAT-3.
- Published
- 2013
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.